My ePortfolio Register   

PD1/ CTLA4 : Upfront or sequentially?

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 17.05.17
Views: 1451

Prof Christoph Höller - Medical University of Vienna, Vienna, Austria

Prof Hoeller speaks with ecancer at EADO 2017 about the timing of combination therapies using PD-1 and CTLA-4 targeted therapies to treat melanoma.

While these targets have been subject to a great deal of investigation independently, Prof Hoeller notes that there is no trial assessing the two in a direct comparison for upfront combination, or one after the other.

He considers the patient subgroups which may benefit most from these differing approaches, based on tumour infiltration and LDH levels, and weighs how toxicity may be managed.

Prof Hoeller also considers how best to assess patient responses to targeted therapies, based on expression of molecular markers including circulating tumour DNA.

Combining PD-1 and CTLA-4 was also discussed by Dr Christian Blank, here.

ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence